These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 12766097)

  • 1. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial.
    Marston WA; Hanft J; Norwood P; Pollak R;
    Diabetes Care; 2003 Jun; 26(6):1701-5. PubMed ID: 12766097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers.
    Gentzkow GD; Iwasaki SD; Hershon KS; Mengel M; Prendergast JJ; Ricotta JJ; Steed DP; Lipkin S
    Diabetes Care; 1996 Apr; 19(4):350-4. PubMed ID: 8729158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis.
    Hanft JR; Surprenant MS
    J Foot Ankle Surg; 2002; 41(5):291-9. PubMed ID: 12400712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the french context.
    Allenet B; Parée F; Lebrun T; Carr L; Posnett J; Martini J; Yvon C
    Diabetes Metab; 2000 Apr; 26(2):125-32. PubMed ID: 10804327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis.
    Frykberg RG; Cazzell SM; Arroyo-Rivera J; Tallis A; Reyzelman AM; Saba F; Warren L; Stouch BC; Gilbert TW
    J Wound Care; 2016 Jul; 25(Sup7):S18-S25. PubMed ID: 29027848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human fibroblast-derived dermal substitute: results from a treatment investigational device exemption (TIDE) study in diabetic foot ulcers.
    Warriner RA; Cardinal M;
    Adv Skin Wound Care; 2011 Jul; 24(7):306-11. PubMed ID: 21685733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, single-blind trial comparing the efficacy of viable cryopreserved placental membrane to human fibroblast-derived dermal substitute for the treatment of chronic diabetic foot ulcers.
    Ananian CE; Dhillon YS; Van Gils CC; Lindsey DC; Otto RJ; Dove CR; Pierce JT; Saunders MC
    Wound Repair Regen; 2018 May; 26(3):274-283. PubMed ID: 30098272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers.
    Curran MP; Plosker GL
    BioDrugs; 2002; 16(6):439-55. PubMed ID: 12463767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator.
    Cazzell S; Vayser D; Pham H; Walters J; Reyzelman A; Samsell B; Dorsch K; Moore M
    Wound Repair Regen; 2017 May; 25(3):483-497. PubMed ID: 28544150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial.
    Veves A; Falanga V; Armstrong DG; Sabolinski ML;
    Diabetes Care; 2001 Feb; 24(2):290-5. PubMed ID: 11213881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of venous leg ulcers with Dermagraft.
    Omar AA; Mavor AI; Jones AM; Homer-Vanniasinkam S
    Eur J Vasc Endovasc Surg; 2004 Jun; 27(6):666-72. PubMed ID: 15121121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High bacterial load in asymptomatic diabetic patients with neurotrophic ulcers retards wound healing after application of Dermagraft.
    Browne AC; Vearncombe M; Sibbald RG
    Ostomy Wound Manage; 2001 Oct; 47(10):44-9. PubMed ID: 11890078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers.
    Harding K; Sumner M; Cardinal M
    Int Wound J; 2013 Apr; 10(2):132-7. PubMed ID: 23506344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective, Randomized, Blinded, Controlled Trial Comparing Transdermal Continuous Oxygen Delivery to Moist Wound Therapy for the Treatment of Diabetic Foot Ulcers.
    Driver VR; Reyzelman A; Kawalec J; French M
    Ostomy Wound Manage; 2017 Apr; 63(4):12-28. PubMed ID: 28448266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective clinical study of 188 consecutive patients to examine the effectiveness of a biologically active cryopreserved human skin allograft (TheraSkin®) on the treatment of diabetic foot ulcers and venous leg ulcers.
    Landsman AS; Cook J; Cook E; Landsman AR; Garrett P; Yoon J; Kirkwood A; Desman E
    Foot Ankle Spec; 2011 Feb; 4(1):29-41. PubMed ID: 21135263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers.
    Naughton G; Mansbridge J; Gentzkow G
    Artif Organs; 1997 Nov; 21(11):1203-10. PubMed ID: 9384327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial.
    Blume PA; Walters J; Payne W; Ayala J; Lantis J
    Diabetes Care; 2008 Apr; 31(4):631-6. PubMed ID: 18162494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular versus acellular matrix devices in the treatment of diabetic foot ulcers: Interim results of a comparative efficacy randomized controlled trial.
    Tchanque-Fossuo CN; Dahle SE; Lev-Tov H; West KIM; Li CS; Rocke DM; Isseroff RR
    J Tissue Eng Regen Med; 2019 Aug; 13(8):1430-1437. PubMed ID: 31070860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft.
    Sanders L; Landsman AS; Landsman A; Keller N; Cook J; Cook E; Hopson M
    Ostomy Wound Manage; 2014 Sep; 60(9):26-38. PubMed ID: 25211605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer.
    Marston WA
    Expert Rev Med Devices; 2004 Sep; 1(1):21-31. PubMed ID: 16293007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.